Rheumatoid Arthritis — What It Is, How It's Diagnosed, and How It's Treated

Short Answer

Rheumatoid arthritis (RA) is a chronic autoimmune disease: your immune system misreads the lining of your joints — the synovium — as a target, and that inflammation can show up as pain, swelling, warmth, stiffness, and fatigue. It often starts in smaller joints and tends to affect both sides of the body, especially the hands, wrists, feet, and ankles; without control, ongoing inflammation can damage cartilage and bone over time. It is “a chronic autoimmune disease contributing to global morbidity and disability”. (niams.nih.gov)

There isn’t one blood test that “proves” RA. Doctors put the pattern together: your symptoms, a joint exam, inflammation tests, imaging when needed, and antibody markers — “conventional markers (rheumatoid factor and anti-cyclic citrullinated peptide)” — while remembering that some people with real RA have normal RF and anti-CCP results. That’s why a negative test shouldn’t be used to dismiss persistent swollen, stiff joints. (niams.nih.gov)

Treatment usually centers on disease-modifying antirheumatic drugs (DMARDs), started early enough to quiet the immune attack before more joint damage becomes permanent. Anti-inflammatory medicines, physical or occupational therapy, movement, sleep, nutrition, and stress recovery can support the plan, but they don’t replace DMARDs when RA is active. (niams.nih.gov)

Because RA flares can feel unpredictable, your day-to-day body signals matter. Resting heart rate, HRV, sleep, and activity won’t diagnose RA or tell you which medication to take, but they can give you and your clinician a clearer context lens: in wearable-device studies, heart rate, HRV, steps, and related physiologic patterns shifted around symptomatic and inflammatory flares, with one study finding changes up to 4 weeks before flare development and another showing machine-learning detection of patient-reported flares from activity-tracker data. (pubmed.ncbi.nlm.nih.gov)

Rheumatoid arthritis at a glance

• What it is — Rheumatoid arthritis is an autoimmune disease: your immune system misreads joint-lining tissue as a threat, so inflammation keeps switching on instead of resolving. In the literature, it is described as “an autoimmune disorder associated with chronic inflammation, progressive deformities of the joints, and limited mobility, especially in the hands, feet, and ankles”. That’s why RA is not just “aches from wear and tear”; it is immune-driven inflammation that can change how joints move over time. (mayoclinic.org)

• Core process — The core process is inflammation inside the synovium — the lining around joints — with immune signals that can spill beyond one joint or one body part. One review summarizes RA as “synovial joint inflammation and different system involvement”. In plain terms: the joint lining gets inflamed, fluid can build up, tissue can thicken, and the same systemic inflammation may affect places such as the skin, eyes, lungs, heart, blood vessels, or nerves. (mayoclinic.org)

• Main manifestations — The classic pattern is pain, swelling, warmth, tenderness, and stiffness in more than one joint — often worse in the morning or after rest — plus fatigue, weakness, or low-grade fever. RA often shows up symmetrically, meaning the same joints on both sides of your body may be involved, especially fingers, hands, wrists, feet, ankles, knees, or elbows. Because RA is systemic, symptoms can also come from organs beyond the joints, not only from the joints themselves. (mayoclinic.org)

• Who it affects — RA is more common in women. In the Global Burden of Disease 2021 analysis, the age-standardized female-to-male prevalence ratio was 2.45, and global RA burden is rising: an estimated 17.6 million people were living with RA in 2020, with prevalence projected to reach 31.7 million by 2050. A psychological-vulnerability review also notes “females showing 1.8-fold increased risk”; read that as a mental-health/adaptation-risk point, not as the overall RA prevalence ratio. (pubmed.ncbi.nlm.nih.gov)

• Key blood markers — The main blood markers are rheumatoid factor (RF) and anti-CCP/ACPA antibodies — “conventional markers (rheumatoid factor and anti-cyclic citrullinated peptide)”. They can support diagnosis and help frame prognosis, but they do not replace the clinical picture. Some people have “seronegative” RA, meaning standard RF and anti-CCP/ACPA tests are negative even though the pattern of inflammatory arthritis fits RA; recent reviews commonly describe seronegative RA as roughly 20–30% of RA cases. (pmc.ncbi.nlm.nih.gov)

• Diagnosis — Diagnosis is clinical plus evidence: your clinician looks at symptoms, joint exam, pattern over time, labs, inflammation markers, and imaging such as X-rays or ultrasound when needed. The 2010 ACR/EULAR classification framework uses joint involvement, serology including RF and/or ACPA, symptom duration, and acute-phase reactants such as CRP or ESR; “definite RA” classification requires synovitis in at least one joint, no better alternative explanation, and a score of 6 or more out of 10. There is no single confirmatory test that proves RA by itself. (pubmed.ncbi.nlm.nih.gov)

• ICD-10 code — M06.9 is the ICD-10-CM code for Rheumatoid arthritis, unspecified. It sits in the rheumatoid arthritis coding area around M05–M06: CDC/NCHS lists M05 as seropositive rheumatoid arthritis and M06 as other rheumatoid arthritis; CDC’s ICD-10-CM system is the U.S. diagnosis-code system used for morbidity coding. (ftp.cdc.gov)

• Treatment — Treatment is built around DMARDs because they target the disease process, not just pain. Current ACR guidance covers conventional synthetic, biologic, and targeted synthetic DMARDs, and states that methotrexate monotherapy is strongly recommended over several alternatives for DMARD-naive patients with moderate-to-high disease activity. NSAIDs and corticosteroids may help symptoms or flares, but they are not the same as disease control; the treatment mix is individualized with your clinician based on disease activity, risks, preferences, and comorbidities. The pharmacology language in one review captures the broad categories: “conventional and biological disease-modifying antirheumatic drugs (DMARDs) and symptomatic response modifiers, like corticosteroids and non-steroidal antirheumatic drugs (NSAIDS)”. (pubmed.ncbi.nlm.nih.gov)

What rheumatoid arthritis is — and why it's more than joint pain

Rheumatoid arthritis is a chronic autoimmune disease. Your immune system is supposed to defend you; in RA, it misfires and attacks the synovium — the thin lining inside your joints. That inflamed lining becomes swollen and chemically active, which is why RA can cause pain, warmth, stiffness, and, over time, cartilage loss, bone erosion, deformity, and reduced movement. It is “a chronic autoimmune disease contributing to global morbidity and disability”, and it often shows up in a pattern that feels very specific: both wrists, both hands, both feet, or both ankles, rather than one isolated “bad joint.” The literature describes RA as “an autoimmune disorder associated with chronic inflammation, progressive deformities of the joints, and limited mobility, especially in the hands, feet, and ankles”. (pubmed.ncbi.nlm.nih.gov)

That symmetry matters because RA is not a simple wear-and-tear problem like osteoarthritis. It is a systemic inflammatory disease: the joint is often where you feel it first, but the immune activity is not locked inside that joint. RA is defined by “synovial joint inflammation and different system involvement” — which means the same inflammatory process can be tied to fatigue, feverish flares, anemia-like exhaustion, and extra-articular problems involving the lungs, heart, skin, nerves, muscles, blood vessels, kidneys, or eyes. That is why “my hands hurt” can come with “my whole body feels off.” (pmc.ncbi.nlm.nih.gov)

RA also tends to travel with other health burdens, which can make symptoms heavier and recovery slower. In one 2026 cross-sectional survey of adults with confirmed RA, “Most participants (98.6%) reported at least one comorbidity, most commonly hypertension, osteoporosis, and cardiovascular disease”. That number comes from one study population, not every person with RA — but it captures the point: RA care has to look beyond swollen joints. Your clinician may monitor inflammation, function, medication safety, cardiovascular risk, bone health, mood, fatigue, and flare patterns because all of these can shape how RA behaves in your real life. (pmc.ncbi.nlm.nih.gov)

This whole-body picture is also why RA is monitored, not just medicated. Modern RA care uses a treat-to-target approach: your care team tracks disease activity with validated measures, then adjusts treatment toward remission or low disease activity rather than waiting for damage to accumulate. Globally, the 2021 Global Burden of Disease analysis estimated that 17.6 million people were living with RA in 2020 and projected 31.7 million by 2050 — a reminder that RA is common enough to need structured, ongoing care, but personal enough that your symptoms, labs, sleep, stress, recovery, and daily function still matter. (pmc.ncbi.nlm.nih.gov)

Symptoms and manifestations of rheumatoid arthritis

The hallmark of RA is symmetric joint involvement — the same joints on both sides of the body — classically in the small joints of the hands and feet. You may feel it as swelling, warmth, tenderness, pain, and that “my joints need a long time to unlock” kind of morning stiffness. Fatigue is common and often underrated: it is not just being tired after a busy day, but a whole-body drain that can come from immune activation, pain, poor sleep, and the effort of moving through inflammation. Because RA is systemic, the manifestations can extend beyond joints to low-grade fever, appetite changes, and involvement of the skin, eyes, lungs, heart, nerves, or blood. (mayoclinic.org)

Flares. RA symptoms fluctuate: periods of relative calm are punctuated by flares — bouts of worsening pain, swelling, stiffness, and fatigue. In one prospective study of people with RA and axial spondyloarthritis, even when disease was well-controlled, “flares were frequent (22.7% of all weekly assessments)”. That matters because a flare is not only “more joint pain.” It can change how much you move, how well you sleep, how much energy you have, and how safe your body feels from the inside. Flares are one of the hardest parts of living with RA precisely because they can seem to come out of nowhere; newer wearable-device research suggests that heart rate, resting heart rate, HRV, and steps can shift in the weeks around symptomatic or inflammatory flares, but these signals are context — not a diagnosis and not a replacement for your rheumatology plan. (pubmed.ncbi.nlm.nih.gov)

The psychological load. RA is not only physical. A review of the disease course notes that “Rheumatoid arthritis (RA) patients face significant psychological challenges alongside physical symptoms”, with “critical intervention periods occurring 3-6 months post-diagnosis and during disease flares”. This is the point many people miss: pain, uncertainty, inflammation, poor sleep, and the fear of the next flare can all push on the same stress systems. Stress may also interact with immune and inflammatory pathways in RA, while depression and pain often travel together. That is why day-to-day self-tracking of stress, recovery, sleep, and activity can be useful context — not because it explains everything, but because it helps you see what your body was carrying before symptoms got loud (see §6). (pmc.ncbi.nlm.nih.gov)

What causes rheumatoid arthritis — and who gets it

RA usually does not come from one clean cause. It develops when an immune system that is already susceptible — partly because of genes, partly because of sex hormones and other biology — meets environmental pressure, and the result is chronic inflammation that targets the joint lining and can also affect the lungs, eyes, blood vessels, skin, and other tissues. NIAMS describes the cause as a combination of genes, environment, and sex-hormone factors; cigarette smoke is one of the clearest environmental exposures studied in that mix. (niams.nih.gov)

That “modifiable side” matters, but it has to be read carefully. An integrated Mendelian-randomization and machine-learning analysis reported that “MR identified obesity, current smoking, sleeplessness, poultry intake, and salt added to food as RA risk factors, while never smoking, pork consumption, and cheese intake were protective”. This does not mean one food caused your RA, or that changing a food can replace DMARD treatment. It means genetic-instrument research is pointing toward body weight, smoking, sleep, and diet-related patterns as signals worth taking seriously — with smoking still the most established and clinically actionable risk factor. A PubMed-indexed meta-analysis found smoking was associated with higher RA risk, especially in rheumatoid-factor-positive RA, men, and heavy smokers; CDC also notes that smoking can increase the risk of RA and can make arthritis worse. (pubmed.ncbi.nlm.nih.gov)

RA is also more common than many people expect. Classic epidemiology reviews place population prevalence around 0.5% to 1%, while a later systematic review of population-based studies estimated worldwide period prevalence at about 0.51%. Incidence and prevalence are not fixed: a Global Burden of Disease 2021 analysis reported rising period effects for both incidence and prevalence, and an Olmsted County, Minnesota study found RA incidence appeared to rise by 2.5% per year in women from 1995 to 2007, but not in men. (pubmed.ncbi.nlm.nih.gov)

Sex and RA. RA is more common in women. NIAMS states that about two to three times as many women as men have RA, and a U.S. lifetime-risk study estimated adult-onset RA risk at 3.6% for women versus 1.7% for men. That sex difference is not just about diagnosis counts; it can shape lived experience, too. In the psychological-trajectory review, risk factors for poorer mental-health outcomes included “gender (females showing 1.8-fold increased risk)”. In plain terms: if you are a woman with RA and the disease hits your mood, sleep, stress tolerance, or sense of control, that is not a personal weakness. It is part of the biology-plus-life-load picture clinicians should take seriously. (niams.nih.gov)

How rheumatoid arthritis is diagnosed — RF, anti-CCP, and seronegative RA

There is no single test that “proves” rheumatoid arthritis. RA is diagnosed from the whole pattern: which joints are swollen or tender, whether the symptoms are symmetrical, how long stiffness and swelling have been going on, what the physical exam shows, whether inflammation markers are elevated, what imaging shows, and whether another condition explains the joint inflammation better. The 2010 ACR/EULAR framework classifies “definite RA” when there is confirmed synovitis in at least one joint, no better alternative diagnosis, and a score of 6 or more out of 10 across joint involvement, serology, acute-phase reactants, and symptom duration. In practice, those criteria support clinical judgment; they do not replace it. (pubmed.ncbi.nlm.nih.gov)

Rheumatoid factor and anti-CCP. The two workhorse blood tests are rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies. A large US testing-patterns analysis describes these as the “conventional markers (rheumatoid factor and anti-cyclic citrullinated peptide)”, alongside newer emerging markers. RF can support the diagnosis, but it is not RA-specific; it can be positive in other autoimmune diseases, infections, and some cancers. Anti-CCP is more specific for RA than RF, so a positive anti-CCP result carries more diagnostic weight when your symptoms fit. Positive RF and anti-CCP can also point to a higher-risk disease pattern, including a greater chance of radiographic joint damage in some studies. (medlineplus.gov)

Seronegative RA. Importantly, not everyone with RA tests positive. Some people have the clinical pattern of RA — inflammatory joint swelling, morning stiffness, symmetrical small-joint involvement, imaging or exam evidence of synovitis — while RF and anti-CCP are negative. This is often called seronegative RA, and it can make diagnosis slower because the “easy” antibody clues are missing. As one biomarker study puts it, RA is “an autoimmune disease for which better biomarkers are needed, especially in seronegative cases”, and it found that “In seronegative RA, diagnostic discrimination declined” for blood-count-based markers. A negative antibody test does not rule RA out if the rest of the picture still looks like RA. (medlineplus.gov)

Ruling out look-alikes. Before settling on RA, clinicians also ask: what else could be driving this pain and swelling? Osteoarthritis can mimic joint pain but is not the same autoimmune process. Gout can inflame a joint because of urate crystals. Lupus can cause joint symptoms as part of a broader autoimmune disease. Psoriatic arthritis can look close to RA, especially when skin or nail psoriasis is subtle or not yet recognized. This is why your clinician may combine blood tests, imaging, joint-fluid testing when needed, and a careful skin, nail, and whole-body exam before naming the diagnosis. (mayoclinic.org)

ICD-10 code. For coding, rheumatoid arthritis sits in the M05–M06 range in ICD-10 materials. In ICD-10-CM, M06.9 is used for “Rheumatoid arthritis, unspecified.” That code is for documentation and billing; it does not tell you by itself how active, severe, seropositive, or seronegative someone’s RA is. (platform.who.int)

Rheumatoid arthritis treatment: DMARDs, methotrexate, and NSAIDs

The modern approach to RA is treat early, treat to target. That means your rheumatology team tries to quiet the immune inflammation before it has time to damage cartilage, bone, tendons, and the lining of the joint — then keeps checking disease activity and adjusting treatment until the agreed target is reached, usually remission or low disease activity. NICE describes treat-to-target as defining a target, using tight control, and adapting treatment based on disease activity; the 2021 ACR guideline also frames RA drug choices as shared clinician-patient decisions that depend on disease activity, comorbidities, safety, and personal preferences. (ncbi.nlm.nih.gov)

Treatment usually works in layers. One layer is disease-modifying therapy — drugs that can slow the disease itself. Another layer is symptom support — medicines and non-drug strategies that help with pain, stiffness, sleep, fatigue, and day-to-day function while the disease-modifying plan is doing its slower work. NSAIDs can help pain and stiffness, but they are used on top of disease-modifying treatment; they do not replace it. (ncbi.nlm.nih.gov)

Disease-modifying drugs (DMARDs)

The backbone of RA treatment is disease-modifying antirheumatic drugs (DMARDs). As one review summarizes, “Treatment of RA includes conventional and biological disease-modifying antirheumatic drugs (DMARDs) and symptomatic response modifiers, like corticosteroids and non-steroidal antirheumatic drugs (NSAIDS)”. In practice this means:

• Conventional synthetic DMARDs (csDMARDs) — usually the first disease-modifying layer; methotrexate is the anchor drug for many people with RA when it is safe and appropriate.

• Biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) — advanced therapies used when conventional DMARDs are not enough, are not tolerated, or are not the right fit for your risk profile.

• NSAIDs and corticosteroids — tools for symptom relief or short-term bridging while DMARDs start working, not medicines that change the long-term immune course by themselves.

DMARDs matter because RA is not just “joint pain.” Inside the joint, immune cells keep sending inflammatory signals into the synovium — the tissue that lines the joint. If that signal stays high, the joint lining thickens, swelling builds, and the surrounding structures can be damaged. A DMARD plan aims upstream: less immune overactivity, less synovial inflammation, fewer flares, and a lower chance of permanent joint damage. (ncbi.nlm.nih.gov)

Methotrexate is the most common first-line conventional DMARD; in one hospital case series, “Methotrexate was part of the treatment regimen for twenty-seven patients, accounting for 90% of the cohort”. That number is from one case series, not a rule for everyone. What matters for you is safety and fit: methotrexate needs clinician-directed dosing, regular monitoring, and a clear plan for side effects, missed doses, infections, pregnancy risk, kidney or liver issues, and drug interactions. The FDA label for methotrexate tablets warns that serious adverse reactions, including death, have been reported; it specifically calls for close monitoring of the bone marrow, gastrointestinal tract, liver, lungs, skin, and kidneys, and warns that accidental once-daily use has led to deaths. (accessdata.fda.gov)

Do not change your methotrexate dose or schedule on your own. That same study warns that “medication non-adherence, particularly self-driven escalation of methotrexate dosage, is a critical risk factor for life-threatening bone marrow suppression”. If your RA feels uncontrolled, that is a reason to contact your rheumatology team — not a reason to “catch up,” double up, or experiment. The next safe step may be blood work, a medication adjustment, switching route or class, adding another DMARD, or treating something else that is amplifying pain, such as infection, anemia, sleep loss, or another pain condition. (accessdata.fda.gov)

Which drug, and when to escalate, is individualized. Some people have refractory RA — disease that remains active or keeps causing symptoms despite multiple advanced therapies. A large real-world analysis studied people initiating a third biologic or targeted synthetic DMARD and noted that “a considerable proportion of patients exhibit refractory disease”. In that study, the third-advanced-therapy group included 692 matched patients, and the authors emphasized higher disease burden, patient-reported symptoms, comorbidities, and unmet needs in this population. (pmc.ncbi.nlm.nih.gov)

That is why escalation is not a simple ladder you climb alone. A biologic, a JAK inhibitor, a different csDMARD combination, a steroid bridge, or a pause because of infection risk can all be “right” in different bodies. Your rheumatologist is weighing inflammation, lab safety, pregnancy plans, liver and kidney function, lung disease, infection history, cardiovascular risk, cancer history, vaccine timing, insurance access, and what you can realistically stick with. The goal is not just a stronger drug. The goal is the safest route to lower disease activity. (pubmed.ncbi.nlm.nih.gov)

For a fuller walkthrough of RA medications — DMARD classes, methotrexate, biologics, and how a rheumatologist builds and adjusts a plan — see our dedicated guide on [rheumatoid arthritis treatment](/rheumatoid-arthritis/treatment/).

Diet and lifestyle as support (not a substitute)

Diet is an adjunct, not a replacement for DMARDs. A narrative review notes that “nutritional interventions are becoming more and more popular due to their ability to alter inflammation”, highlighting anti-inflammatory patterns, including omega-3–rich foods, while cautioning against highly processed carbohydrates and excess sugars. That is useful framing — but food does not switch off RA the way a disease-modifying plan is designed to. Think of diet as terrain: it can affect inflammation, weight, blood sugar, cardiovascular risk, gut comfort, and energy. It should not be used as a substitute for prescription treatment.

Lifestyle support still matters because your immune system does not live separately from the rest of you. Smoking can raise RA risk and make the disease worse; excess weight can add mechanical load to painful joints and is linked with higher RA risk; poor sleep can turn pain volume up and make fatigue feel heavier. Movement, when it is matched to your joints and your current flare state, can strengthen the muscles around joints, reduce stiffness, improve energy, support sleep, and help you stay functional. The 2022 ACR guideline for exercise, rehabilitation, diet, and integrative care says these approaches are used in conjunction with DMARDs, and it gives consistent exercise a strong recommendation for RA management. (mayoclinic.org)

Note: RA treatment is prescription-only and monitored. This section describes drug classes and general strategy; specific drugs, doses, schedules, lab timing, and combinations are decided by a rheumatologist. The ACR guideline is explicit that recommendations support shared decision-making and do not override individualized clinician judgment, and FDA labeling reinforces that methotrexate requires careful use and monitoring because medication errors and serious toxicities can be dangerous. (pubmed.ncbi.nlm.nih.gov)

Living with RA: flares, comorbidities, and what tracking can add

RA is a long-game condition. Symptoms can quiet down, then surge again in flares — weeks or days when inflammation, pain, stiffness, fatigue, and function all shift at once. And because RA is systemic, the day-to-day work is not just “how are my joints?” It is also “what else is this inflammation pulling into the picture?” (mayoclinic.org)

Comorbidities. RA rarely travels alone. The same immune-driven inflammation that attacks the joint lining can also affect the body beyond the joints, including the heart, blood vessels, lungs, and bones. In one patient-reported study, “Most participants (98.6%) reported at least one comorbidity, most commonly hypertension, osteoporosis, and cardiovascular disease” — a reminder that RA care has to include cardiovascular and bone health, not just pain control. Blood pressure, cholesterol, fracture risk, steroid exposure, movement tolerance, shortness of breath, and fatigue all belong in the conversation with your rheumatology team. (pmc.ncbi.nlm.nih.gov)

The mental-health dimension. RA also asks your nervous system to live with uncertainty: Will tomorrow be a good hand day? Will this flare pass? Will the medication work? That load is not “just stress.” Because “Rheumatoid arthritis (RA) patients face significant psychological challenges alongside physical symptoms”, and the highest-risk windows are “critical intervention periods occurring 3-6 months post-diagnosis and during disease flares”, mood, sleep, stress, pain sensitivity, and coping capacity are part of the clinical picture — not a side issue. If anxiety or depression rises after diagnosis or during flares, that is a signal to ask for support early, not a personal failure. (pmc.ncbi.nlm.nih.gov)

Where physiological tracking fits — a context lens. RA flares do not only show up as pain. They can also show up in the body’s background signals: a higher resting heart rate, lower HRV, disrupted sleep, fewer steps, or a recovery pattern that feels “off” before your joints fully declare a flare. Research using consumer wearables has found that “changes in physiological metrics, collected from wearable devices, identify and precede the development of both symptomatic and inflammatory RA flares”, with devices “collecting heart rate (HR), resting heart rate (RHR), heart rate variability (HRV), and steps”, and “All metrics were altered up to 4 weeks prior to inflammatory and symptomatic flare development”. A separate machine-learning study of activity trackers concluded that “the correct detection of flares by machine-learning processing of activity tracker data provides a framework for future studies of remote-control monitoring of disease activity”. The wearable study’s authors frame the takeaway carefully: “This suggests the potential use of wearable devices for disease monitoring and flare prediction”. (pmc.ncbi.nlm.nih.gov)

This is the lens Welltory can add for people with RA: not a diagnosis, not a CRP test, not a replacement for imaging, medication, or your rheumatologist’s exam — but a way to watch your own resting heart rate, HRV, sleep, and activity patterns over time. If your RHR starts creeping up, HRV drops, sleep fragments, and steps fall before your joints flare, that pattern is worth noting. It gives you context: what your body looked like before, during, and after a flare; what stress or poor sleep may have been doing in the background; and what recovery looked like when treatment or rest helped. Tracking is context, not medicine — but good context can make the next appointment more concrete.

How we made it

Made with AI tools, then edited, fact-checked, and medically reviewed by the Welltory team.

The wearable-device findings on heart rate, resting heart rate, HRV, and steps around RA flares come from independent published research, not from Welltory's own user data; Welltory offers a way to track those same signals over time as personal context, not a diagnosis.

Discounts for blog readers: up to 36% off

See what affects your energy, stress, sleep, and daily state with Welltory

Explore your data